NCT04396340 is a Phase 1 clinical trial of XMT-1592 in Ovarian Cancer, sponsored by Mersana Therapeutics.

Who is sponsoring NCT04396340?

NCT04396340 is sponsored by Mersana Therapeutics.

What drugs are being tested in NCT04396340?

Interventions in NCT04396340: XMT-1592.

What condition does NCT04396340 study?

NCT04396340 studies Ovarian Cancer, Nonsmall Cell Lung Cancer.

Is NCT04396340 still recruiting?

NCT04396340 is currently terminated. Last updated 15 March 2024.

Last reviewed 2024-03-15 · How we verify

NCT04396340

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Terminated Phase 1 Last updated 15 March 2024

What this trial tests

Phase 1 trial testing XMT-1592 in Ovarian Cancer in 31 participants. Terminated before completion.

Timeline

11 May 2020

Primary endpoint
30 September 2022

30 September 2022

Quick facts

Lead sponsor	Mersana Therapeutics
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	11 May 2020
Primary completion	30 September 2022
Estimated completion	30 September 2022
Sites	1 location across United States

Drugs / interventions tested

XMT-1592 — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Nonsmall Cell Lung Cancer — all drugs for Nonsmall Cell Lung Cancer →

Sponsor

Mersana Therapeutics — full company profile →

Who can join

Adults 18 to 95, any sex, with Ovarian Cancer or Nonsmall Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U, Parakh S, Gan HK, Scott AM. · · 2020 · cited 283× · PMID 33081383 · DOI 10.3390/molecules25204764
Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
Site-specific conjugation of native antibody.
Sadiki A, Vaidya SR, Abdollahi M, Bhardwaj G, et al · · 2020 · cited 62× · PMID 33644685 · DOI 10.1093/abt/tbaa027
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
Abuhelwa Z, Alloghbi A, Nagasaka M. · · 2022 · cited 42× · PMID 35472631 · DOI 10.1016/j.ctrv.2022.102393
Nutrient transporters: connecting cancer metabolism to therapeutic opportunities.
Nwosu ZC, Song MG, di Magliano MP, Lyssiotis CA, et al · · 2023 · cited 29× · PMID 36739364 · DOI 10.1038/s41388-023-02593-x
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Zhou L, Lu Y, Liu W, Wang S, et al · · 2024 · cited 27× · PMID 38429828 · DOI 10.1186/s40164-024-00493-8
The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
Liu X, Deng J, Zhang R, Xing J, et al · · 2023 · cited 15× · PMID 38162667 · DOI 10.3389/fimmu.2023.1335252
Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer.
Nurgalieva AK, Popov VE, Skripova VS, Bulatova LF, et al · · 2021 · cited 15× · PMID 34504954 · DOI 10.1016/j.bbrep.2021.101104

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Mersana Therapeutics trials

Trials by the same sponsor.

NCT05329545 — Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) · Phase 3 · terminated
NCT04907968 — Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer · Phase 1 · terminated
NCT06517485 — First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b · Phase 1 · completed
NCT06517433 — First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b · Phase 1 · completed
NCT03319628 — First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04396340 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mersana Therapeutics
Last refreshed: 15 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04396340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing